Real-time · AI · Cross-signal
Yuhan just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on Yuhan, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
Yuhan Corp. receives 80 billion won royalty payment from Janssen for FDA-approved cancer drug Leclaza
Nov 14, 2024•over 1 year ago
Contract Type
partnership
BiotechnologyPharmaceutical
Description
Yuhan Corp., a Korean pharmaceutical company, has received a record-breaking third-quarter revenue of 598.8 billion won, driven by the first Korean cancer drug, Leclaza, receiving FDA approval in August. The company earned an 80 billion won royalty payment from Janssen, which licensed Leclaza. Yuhan Corp. expects to receive additional royalties from future U.S
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months